	US 12,233,114 B2
	Method for treating diabetes
Simon Skibsted, Princeton, NJ (US); and Kajsa Kvist, Holte (DK)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Feb. 8, 2022, as Appl. No. 17/667,223.
Application 17/667,223 is a continuation of application No. 16/463,598, granted, now 11,278,596, previously published as PCT/EP2017/080600, filed on Nov. 28, 2017.
Claims priority of application No. 16200906 (EP), filed on Nov. 28, 2016; and application No. 17174682 (EP), filed on Jun. 7, 2017.
Prior Publication US 2022/0160840 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/28 (2006.01); A61P 3/10 (2006.01); A61P 9/00 (2006.01)

CPC A61K 38/28 (2013.01) [A61P 3/10 (2018.01); A61P 9/00 (2018.01)]

15 Claims

1. A method for treating diabetes comprising:

administration of a basal insulin in a therapeutically effective amount to a subject in need thereof, wherein said subject has a cardiovascular disease or is at risk of developing a cardiovascular disease and wherein said basal insulin is insulin degludec,

wherein said method delays or reduces major adverse cardiovascular event (MACE),

wherein said MACE is selected from cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke, and wherein said MACE is reduced from about 5% to about 15% compared to placebo.